HC Wainwright Analysts Decrease Earnings Estimates for COLL

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Investment analysts at HC Wainwright cut their Q2 2026 earnings per share estimates for shares of Collegium Pharmaceutical in a report issued on Thursday, April 23rd. HC Wainwright analyst B. Folkes now forecasts that the specialty pharmaceutical company will post earnings of $1.48 per share for the quarter, down from their prior estimate of $1.65. HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Collegium Pharmaceutical’s current full-year earnings is $6.51 per share. HC Wainwright also issued estimates for Collegium Pharmaceutical’s Q4 2026 earnings at $2.14 EPS and FY2026 earnings at $6.27 EPS.

A number of other equities research analysts have also weighed in on the company. Wall Street Zen lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Barclays decreased their price target on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a research note on Friday, January 9th. Needham & Company LLC reissued a “buy” rating and set a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Truist Financial set a $58.00 price target on Collegium Pharmaceutical in a research note on Tuesday, February 10th. Finally, Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $53.40.

Collegium Pharmaceutical Price Performance

Shares of COLL opened at $32.28 on Friday. Collegium Pharmaceutical has a twelve month low of $25.98 and a twelve month high of $50.79. The stock’s 50 day moving average is $37.07 and its two-hundred day moving average is $41.41. The firm has a market capitalization of $1.05 billion, a PE ratio of 18.88 and a beta of 0.77. The company has a current ratio of 1.57, a quick ratio of 1.48 and a debt-to-equity ratio of 2.59.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The business had revenue of $205.45 million during the quarter, compared to analysts’ expectations of $206.36 million. During the same period in the prior year, the firm posted $1.77 EPS. Collegium Pharmaceutical’s revenue for the quarter was up 12.9% compared to the same quarter last year.

Insider Activity at Collegium Pharmaceutical

In related news, EVP David Dieter sold 13,976 shares of Collegium Pharmaceutical stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total transaction of $488,041.92. Following the completion of the transaction, the executive vice president directly owned 77,071 shares in the company, valued at $2,691,319.32. The trade was a 15.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Scott Dreyer sold 49,976 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $40.41, for a total value of $2,019,530.16. Following the transaction, the executive vice president owned 71,770 shares of the company’s stock, valued at $2,900,225.70. This represents a 41.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.85% of the stock is owned by insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several hedge funds have recently bought and sold shares of COLL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Collegium Pharmaceutical by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock worth $569,000 after buying an additional 825 shares in the last quarter. Millennium Management LLC increased its position in Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after buying an additional 461,914 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Collegium Pharmaceutical by 7.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock worth $2,120,000 after buying an additional 4,625 shares in the last quarter. Jane Street Group LLC increased its position in Collegium Pharmaceutical by 218.7% during the first quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock worth $3,926,000 after buying an additional 90,255 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in Collegium Pharmaceutical by 3.7% during the second quarter. JPMorgan Chase & Co. now owns 72,068 shares of the specialty pharmaceutical company’s stock worth $2,131,000 after buying an additional 2,592 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.